Another agent, ociperlimab, is also being evaluated in combination with the anti-PD-1 tislelizumab in the phase III ADVANTIG-302 trial (NCT04746924) for advanced NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.